Release – Comtech Telecommunications Corp. to Participate in NobleCon18 Investor Conference



Comtech Telecommunications Corp. to Participate in NobleCon18 Investor Conference

Research, News, and Market Data on Comtech Telecommunications

 

MELVILLE, N.Y.–(BUSINESS WIRE)–Apr. 13, 2022– 
April 13, 2022— 
Comtech Telecommunications Corp. (NASDAQ: CMTL), a leading global provider of next-generation 911 emergency systems and secure wireless communications technologies, announced today that it will present at NobleCon18, Noble Capital Markets’ Eighteenth Annual Investor Conference at the 
Hard Rock Hotel & Casino
Hollywood, Florida on 
Wednesday, April 20, 2022 at 
4:30 pm EDT.

Comtech management will provide an overview of the Company and its business opportunities. There is also the opportunity to meet with management at our breakout sessions scheduled for 
Wednesday, April 20, 2022 at 
1:45 pm EDT and 
Thursday, April 21, 2022 at 
12:15 pm EDT.

A webcast of the presentation will be available on Comtech’s website at www.comtechtel.com and as part of a complete catalog of presentations available at Noble Capital Markets’ Conference website www.nobleconference.com and on Channelchek www.channelchek.com the investor portal created by Noble. The webcast is expected to be archived on Comtech’s website for a limited time following the event.

About Comtech

Comtech Telecommunications Corp. is a leading global provider of next-generation 911 emergency systems and secure wireless communications technologies to commercial and government customers around the world. Headquartered in 
Melville, New York and with a passion for customer success, 
Comtech designs, produces and markets advanced and secure wireless solutions.

About Noble Capital Markets, Inc.

Noble Capital Markets (“Noble”) is a research driven investment bank that has supported small & microcap companies since 1984. As a 
FINRA and 
SEC licensed broker dealer Noble provides institutional-quality equity research, merchant and investment banking, and order execution services. In 2005, Noble established NobleCon, an investor conference that has grown substantially over the last decade. Noble launched www.channelchek.com in 2018 – an investor community dedicated exclusively to public small and micro-cap companies and their industries. Channelchek is the first service to offer institutional-quality research to the public, for FREE at every level without a subscription. More than 6,000 public emerging growth companies are listed on the site, with growing content including research, webcasts, podcasts, and balanced news.

Certain information in this press release contains statements that are forward-looking in nature and involve certain significant risks and uncertainties. Actual results could differ materially from such forward-looking information. The Company’s 
Securities and Exchange Commission filings identify many such risks and uncertainties. Any forward-looking information in this press release is qualified in its entirety by the risks and uncertainties described in such 
Securities and Exchange Commission filings.

Comtech Investor Relations
Robert Samuels
631-962-7102
robert.samuels@comtech.com

Source: 
Comtech Telecommunications Corp.

Release – FAT Brands Quick-Service Division Continues Strong Growth Momentum



FAT Brands’ Quick-Service Division Continues Strong Growth Momentum, Signing Development Agreements Totaling Over 50 New Stores

Research, News, and Market Data on FAT Brands

 

Global Franchise Group, Now FAT Brands’ Quick-Service Division, Experiences Strong Franchisee Demand Following June 2021 Acquisition

LOS ANGELES, April 13, 2022 (GLOBE NEWSWIRE) — FAT (Fresh. Authentic. Tasty.) Brands Inc., parent company of Round Table Pizza, Great American Cookies, Marble Slab Creamery, and 14 other restaurant concepts, announces its Quick-Service Division has signed 20 new development deals, totaling over 50 additional units, following the acquisition of Global Franchise Group in June 2021. The acquisition marked FAT Brands’ foray into both the snack and pizza categories, adding the following brands: Round Table Pizza, Great American Cookies, Marble Slab Creamery, Hot Dog on a Stick and Pretzelmaker.

Since the formation of the Quick-Service Division, composed of the brands from the Global Franchise Group acquisition, demand has been high for new franchises, in particular, amongst existing franchisees. The Great American Cookies & Marble Slab Creamery co-branded restaurant model continues to be attractive to new and existing franchisees alike with new deals in areas including Nashville, Tenn., Houston and Shreveport, La. Round Table Pizza is also deepening its presence in California, with agreements signed for nine new locations to open throughout the state in the coming years. Additional deals were also signed for Great American Cookies, Marble Slab Creamery, Hot Dog on a Stick and Pretzelmaker. In total, there are over 150 units in the pipeline in the Quick-Service Division with over 30 locations set to open their doors in 2022.

“While the pandemic has certainly impacted the restaurant space, we are so fortunate to have a deep store pipeline in addition to solid same-store-sales growth,” said Jenn Johnston, President of FAT Brands’ Quick-Service Division. “In the fourth quarter of 2021, same-store-sales within the division were up 10.6% in comparison to 2019 and up 16.1% in comparison to 2020. Since joining FAT Brands, we have increased our scale, offered franchisees access to new services, and have formed new synergies at both the brand and corporate level.”

“The Quick-Service brands have been a strong addition to the FAT Brands portfolio,” said Taylor Wiederhorn, Chief Development Officer of FAT Brands. “In just nine months we have made incredible traction in not only integrating the brands, but also in signing new development deals. We look forward to continuing to broaden the division’s presence on a global level in the years to come.”

For more information on FAT Brands, please visit www.fatbrands.com.

About FAT (Fresh. Authentic. Tasty.) Brands
FAT Brands (NASDAQ: FAT) is a leading global franchising company that strategically acquires, markets, and develops fast casual, quick-service, casual dining, and polished casual dining concepts around the world. The Company currently owns 17 restaurant brands: Round Table Pizza, Fatburger, Marble Slab Creamery, Johnny Rockets, Fazoli’s, Twin Peaks, Great American Cookies, Hot Dog on a Stick, Buffalo’s Cafe & Express, Hurricane Grill & Wings, Pretzelmaker, Elevation Burger, Native Grill & Wings, Yalla Mediterranean and Ponderosa and Bonanza Steakhouses, and franchises over 2,300 units worldwide. For more information on FAT Brands, please visit www.fatbrands.com.

Forward Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements relating to the timing and performance of new store openings. Forward-looking statements reflect expectations of FAT Brands Inc. (“we”, “our” or the “Company”) concerning the future and are subject to significant business, economic and competitive risks, uncertainties and contingencies, including but not limited to uncertainties surrounding the severity, duration and effects of the COVID-19 pandemic. These factors are difficult to predict and beyond our control, and could cause our actual results to differ materially from those expressed or implied in such forward-looking statements. We refer you to the documents that we file from time to time with the Securities and Exchange Commission, such as our reports on Form 10-K, Form 10-Q and Form 8-K, for a discussion of these and other factors. We undertake no obligation to update any forward-looking statement to reflect events or circumstances occurring after the date of this press release.

MEDIA CONTACT:
Erin Mandzik, FAT Brands
emandzik@fatbrands.com
860-212-6509

Release – Ceapro Inc. Reports Fourth Quarter and Full Year 2021 Financial Results and Operational Highlights



Ceapro Inc. Reports Fourth Quarter and Full Year 2021 Financial Results and Operational Highlights

Research, News, and Market Data on Ceapro

 

– FY 2021 record sales of $17,200,000 compared to $15,100,000 for FY 2020, representing a 14% increase year over year; Ceapro’s best sales performance in Company history

– Net profit of $2,842,000 for the full year of 2021 compared to a net profit of 1,856,000 in 2020, a year over year increase of 53%

 R&D activities focused on the development of avenanthramide pills for a Phase 1 study, on advancing the development of innovative delivery systems with new chemical complexes and on processing yeast beta glucan from various sources for the development of an immune booster and as a potential inhalable therapeutic for COVID-19

 Achieved record production levels despite COVID-19 pandemic situation, supply chain and transportation logistic challenges

EDMONTON, Alberta, April 13, 2022 (GLOBE NEWSWIRE) — Ceapro Inc. (TSX-V: CZO, OTCQX: CRPOF) (“Ceapro” or the “Company”), a growth-stage biotechnology company focused on the development and commercialization of active ingredients for healthcare and cosmetic industries, today announced operational highlights and financial results for the fourth quarter and full year ended December 31, 2021.

“We are thrilled with achievements made in 2021 on all fronts from production operations to research and development, allowing us to expand our pipeline to build a high value life sciences Company focused on immune and inflammation-based diseases. A 14% year over year increase in sales for our base business is absolutely remarkable especially during such a year marked by a continued COVID-19 pandemic, inflationary pressure, issues related to availability of inputs, persistently high logistical transportation costs and labour scarcity. Despite these challenges, our team worked tirelessly to meet strong demand for our products and deliver one of the best ever performances in the Company’s history. I thank everyone wholeheartedly for their resilience and dedication,” stated Gilles Gagnon, M.Sc., MBA, President and CEO, of Ceapro. “In addition to excellent financial and operational results, we had many key highlights over the course of the year and are committed to building on these achievements.”

2021 Corporate and Operational Highlights

Pipeline Development

Avenanthramides:

  • Announced expanded collaboration with Montreal Heart Institute (MHI) with new clinical study evaluating flagship product, avenanthramides, as a new potential pharmaceutical product. This Phase 1 safety and tolerability study will be led by renowned Dr. Jean-Claude Tardif. Published positive results from Ceapro’s previously conducted study evaluating anti-inflammatory properties of low doses of avenanthramides in exercise-induced inflammation paved the way for this clinical trial.
  • Agreement signed with Corealis to formulate 30mg and 240mg dosage pills to be used in Phase 1 study with MHI.
  • Completed physical characterization of avenanthramides and continued to monitor stability studies with new powder formulations.
  • Completed the Phase 1 study protocol which expects to enroll approximately 72 patients.

Oat Beta Glucan:

  • Completed pilot clinical trial evaluating oat beta glucan in patients with high cholesterol levels. While there were positive signals that beta glucan nutraceutical formulation may offer appreciable health benefits as indicated with approved Health Canada’s beta glucan monograph (Natural Product Division), the study did not achieve in a statistically significant manner the expected primary endpoint related to a decrease of low-density lipoproteins cholesterol when using Ceapro’s pill dosage form.
  • Announced research agreement with Boston-based Angiogenesis Foundation to assess in vivo bioefficacy of oat beta glucan and avenanthramides in angiogenesis, blood vessel repairs, and wounds to assess healing and tissue regeneration in various inflammation-based diseases and conditions like COVID-19 presenting damages of the lung blood vessels.

Yeast Beta Glucan (YBG)

  • Analyzed and screened YBG feedstock from numerous global suppliers to select ideal sources for best possible product.
  • Identified process conditions for YBG improving morphology of YBG processed using PGX Technology (PGX-YBG) to boost immunomodulating activity.
  • Further developed custom-shape formulations of PGX-YBG for oral administration.
  • Obtained further evidence confirming that PGX-YBG is suitable for lung inhalation.
  • Demonstrated, in vitro, that PGX processed YBG can prevent the activation of macrophages toward a pro-fibrotic phenotype which, according to experts in the field, is seen as a viable therapeutic strategy toward fibrotic disease.

    • PGX-YBG binds to specific receptors (Dectin 1) located on macrophages responsible for the cascade of immunomodulating events when activated.
    • McMaster’s research team discovered a new mechanism of action as per PGX-YBG’s ability to reprogram macrophages on its own.
  • Continuing PGX-YBG project with McMaster University to assess preclinical animal models to determine posology.
  • Initiated studies with a medical device manufacturer to assess aerosol/nebulizer device for inhalation of YBG.
  • Proved, using an in vitro study, that the Company’s PGX Technology maintains the integrity of the YBG molecular structure and enhances its microscopic morphology which leads to a boost in its immunomodulatory activity without generating proinflammatory reaction. Based on these attributes PGX-YBG is poised to become a key strategic asset for the Company.

New Chemical Complexes / Delivery Systems:

  • Announced the successful completion of a long-term research program conducted with University of Alberta. This screening program allowed Ceapro to retain the most promising products, such as PGX-alginate, and expand the PGX-processed products pipeline. Combination of alginate and YBG, leading to tunable PGX composites, are now viewed as the most promising products developed from this research program.
  • Pursued bioavailability studies with University of Alberta for new chemical complexes YBG-CoQ10, alginate-CoQ10 and the newly formed alginate-YBG-CoQ10. Results are expected in Q3 2022.

Technology:

  • Continued significant technical improvements of the existing PGX plant in Edmonton to develop equipment for the production of PGX-YBG for the purpose of generating material suitable for nutraceutical and lung delivery.
  • Ongoing engineering design in collaboration with experts in the field for designing and building a PGX processing commercial unit. Alginate and yeast beta glucan would be the first products to be processed at large scale level. Given regulatory requirements and to accelerate market entry, yeast beta glucan as a standalone and/or in combination with alginate will be developed at first as a nutraceutical/immune booster.
  • Pursued installment in Edmonton of a commercial scale unit for loading of bioactives onto PGX-processed biopolymers. This system allows loading of active pharmaceutical ingredients, like ibuprofen, onto thin soluble PGX alginate strips for wound healing or oral applications.
  • Continued projects with University of Alberta and McMaster University for the development of potential delivery systems for multiple applications in healthcare.

Bioprocessing Operations

  • Ceapro’s dedicated production team successfully responded to the growing market demand for the cosmeceutical base business by producing over 290 metric tons of active ingredients in 2021, a 20% increase over the previous year.
  • Received renewal of the Site License from the Health Canada Natural Product Directorate. This License enables the Company to manufacture, package, label, release and distribute final products.

Corporate

  • Fully repaid loan with Canadian Agricultural Adaptation Program (CAAP).
  • Effective December 31, 2021, the Company wound up Ceapro Technology Inc., Ceapro Active Ingredients Inc. and Ceapro BioEnergy Inc. into the Company and dissolved Ceapro USA Inc. JuventeDC Inc. remains the only active fully owned subsidiary of Ceapro Inc.
  • Announced expansion of a grant from National Research Council of Canada Industrial Research Assistance Program (NRC-IRAP) to further develop the patented PGX Technology to increase its innovation capacity by designing the first pharmaceutical PGX processing unit along with bioactive impregnation and loading units.
  • Pursued out-licensing discussions for PGX-processed new chemical complexes.

Subsequent to Year End

  • Signed a Supply and Distribution Agreement with Symrise securing the long-term sustainability of Ceapro’s base business.
  • Appointed Mr. Ronnie Miller, former President & CEO of Roche Canada for the last 22 years, to the Company’s Board of Directors.

Financial Highlights for the Fourth Quarter and the Full Year 2021 Ended December 31, 2021

  • Total sales of $3,562,000 for the fourth quarter of 2021 and $17,200,000 for the full year of 2021 compared to $2,706,000 and $15,100,000 for the comparative periods in 2020. These respective increases of 32% for Q4, 2021 and 14% for the full year 2021 were driven by volume sales increases in all of the Company’s primary products. The increase in revenue occurred despite being offset by a lower U.S. dollar relative to the Canadian dollar compared to the prior year, which negatively impacted revenue by approximately $1,358,000 for the full year 2021.
  • Net profit of $776,000 for the fourth quarter of 2021 and a net profit of $2,842,000 for the full year of 2021 compared to a net loss of $539,000 and a net profit of 1,856,000 for the comparative periods in 2020, a year over year increase of 53.1% for the full year 2021. These results reflect a full year of operations in one production site only as compared to year 2020 that was marked by the completion of the decommissioning of Leduc manufacturing site and the final integration of production operations in the Edmonton facility. Margins improved on an annual basis from 50% in 2020 to 56% in 2021.
  • Cash generated from operations of $3,510,000, for the full year 2021.
  • Positive working capital balance of $10,755,000 as of December 31, 2021.

“While the Company’s business has not been significantly impacted by the COVID-19 pandemic, management remains very vigilant in ensuring the highest level of safety for Ceapro’s employees. Depending on the evolution of this pandemic situation and assuming minimal supply chain disruptions, I strongly believe the prospects for the Company remain very strong for the upcoming year. We expect Ceapro’s cosmeceuticals base business to continue growing and provide positive cash flows to support the expansion to a new business model to a high value life science/biopharmaceutical company involved in nutraceuticals and pharmaceuticals. We then expect to further invest into R&D to initiate an early clinical trial with our newly developed pill of avenanthramide, to continue the development of new chemical complexes as potential delivery systems for bioactives and to emphasize our current efforts for the development and assessment of yeast beta glucan as immune booster and as potential inhalable therapeutics for lung fibrotic diseases including COVID 19 conditions,” added Mr. Gagnon.

“Additionally, results from bioavailability studies with new chemical complexes and results with yeast beta glucan as an immune booster will drive decisions for the magnitude of capital expenditures to be incurred for the building of a commercial scale unit for PGX Technology. Based on a very solid foundation, a highly competent team, a healthy balance sheet and a very strong technology and product portfolio with the potential to access key large markets, we have all the key components for success,” concluded Mr. Gagnon.


CEAPRO INC.        
Consolidated Balance Sheets        
         
         
  December 31,   December 31,  
  2021   2020  
  $   $  
         
ASSETS        
Current Assets        
Cash and cash equivalents 7,780,989   5,369,029  
Trade receivables 2,092,842   2,019,723  
Other receivables 45,850   102,224  
Inventories (note 3) 1,644,893   1,210,079  
Prepaid expenses and deposits 162,919   348,845  
         
Total Current Assets 11,727,493   9,049,900  
         
Non-Current Assets        
Investment tax credits receivable 766,629   607,700  
Deposits 79,539   82,124  
Licences (note 4) 15,551   18,514  
Property and equipment (note 5) 17,499,774   18,591,189  
Deferred tax assets (note 13 (b)) 439,063   874,304  
         
Total Non-Current Assets 18,800,556   20,173,831  
         
TOTAL ASSETS 30,528,049   29,223,731  
         
LIABILITIES AND EQUITY        
Current Liabilities        
Accounts payable and accrued liabilities 682,057   1,067,622  
Current portion of lease liabilities (note 6) 290,055   250,658  
Current portion of CAAP loan (note 8)   72,263  
         
Total Current Liabilities 972,112   1,390,543  
         
Non-Current Liabilities        
Long-term lease liabilities (note 6) 2,358,862   2,648,917  
Deferred tax liabilities (note 13 (b))   874,304  
         
Total Non-Current Liabilities 2,358,862   3,523,221  
         
TOTAL LIABILITIES 3,330,974   4,913,764  
         
Equity        
Share capital (note 7 (b)) 16,557,401   16,511,067  
Contributed surplus (note 7 (e)) 4,680,690   4,682,393  
Retained earnings 5,958,984   3,116,507  
         
Total Equity 27,197,075   24,309,967  
         
TOTAL LIABILITIES AND EQUITY 30,528,049   29,223,731  
         



CEAPRO INC.    
Consolidated Statements of Net Income and Comprehensive Income
     
   
   
  2021   2020  
Years Ended December 31, $   $  
     
Revenue (note 15) 17,195,329   15,121,282  
Cost of goods sold 7,506,036   7,498,996  
     
Gross margin 9,689,293   7,622,286  
     
Research and product development 3,779,102   1,881,883  
General and administration 3,239,672   3,282,754  
Sales and marketing 47,119   111,044  
Finance costs (note 11) 206,891   231,271  
     
Income from operations 2,416,509   2,115,334  
     
Other income (expense) (note 10) 202,281   (259,234 )
     
Income before tax 2,618,790   1,856,100  
     
Income taxes    
Current tax expense (note 13 (a)) 215,376    
Deferred tax benefit (note 13 (a)) (439,063 )  
     
Income tax benefit (223,687 )  
     
Total net income and comprehensive income for the year 2,842,477   1,856,100  
     
Net income per common share (note 20):    
Basic 0.04   0.02  
Diluted 0.04   0.02  
     
Weighted average number of common shares outstanding (note 20):    
Basic 77,673,804   77,594,629  
Diluted 78,590,706   78,143,033  
     



CEAPRO INC.    
Consolidated Statements of Cash Flows    
     
     
     
  2021   2020  
Years Ended December 31, $   $  
OPERATING ACTIVITIES    
Net income for the year 2,842,477   1,856,100  
Adjustments for items not involving cash    
Finance costs 140,270   153,538  
Transaction costs   1,108  
Depreciation and amortization 1,880,748   1,841,033  
Gain on disposal of equipment (5,000 )  
Accretion 11,621   21,625  
Income tax benefit (439,063 )  
Share-based payments 17,906   136,796  
  4,448,959   4,010,200  
CHANGES IN NON-CASH WORKING CAPITAL ITEMS    
Trade receivables (73,119 ) 1,639,818  
Other receivables 56,374   (55,412 )
Investment tax credits receivable (158,929 )  
Inventories (434,814 ) (541,074 )
Prepaid expenses and deposits 111,044   (88,839 )
Accounts payable and accrued liabilities relating to operating activities (298,765 ) (358,136 )
  (798,209 ) 596,357  
Net income for the year adjusted for non-cash and working capital items 3,650,750   4,606,557  
Interest paid (140,270 ) (153,538 )
CASH GENERATED FROM OPERATIONS 3,510,480   4,453,019  
INVESTING ACTIVITIES    
Purchase of property and equipment (689,431 ) (528,707 )
Purchase of leasehold improvements (19,472 ) (12,870 )
Proceeds from sale of equipment 5,000   353  
Deposits relating to the purchase of equipment   (77,467 )
Accounts payable and accrued liabilities relating to investing activities (86,800 ) 134,554  
CASH USED IN INVESTING ACTIVITIES (790,703 ) (484,137 )
FINANCING ACTIVITIES    
Stock options exercised 26,725   4,897  
Repayment of long-term debt   (112,973 )
Repayment of CAAP loan (83,884 ) (83,884 )
Repayment of lease liabilities (250,658 ) (265,088 )
CASH USED IN FINANCING ACTIVITIES (307,817 ) (457,048 )
Increase in cash and cash equivalents 2,411,960   3,511,834  
     
Cash and cash equivalents at beginning of the year 5,369,029   1,857,195  
     
Cash and cash equivalents at end of the year 7,780,989   5,369,029  


The complete financial statements are available for review on SEDAR at https://sedar.com/Ceapro and on the Company’s website at www.ceapro.com.

About Ceapro Inc.

Ceapro Inc. is a Canadian biotechnology company involved in the development of proprietary extraction technology and the application of this technology to the production of extracts and “active ingredients” from oats and other renewable plant resources. Ceapro adds further value to its extracts by supporting their use in cosmeceutical, nutraceutical, and therapeutics products for humans and animals. The Company has a broad range of expertise in natural product chemistry, microbiology, biochemistry, immunology and process engineering. These skills merge in the fields of active ingredients, biopharmaceuticals and drug-delivery solutions. For more information on Ceapro, please visit the Company’s website at www.ceapro.com.

For more information contact:

Jenene Thomas
JTC Team, LLC
Investor Relations and Corporate Communications Advisor
T (US): +1 (833) 475-8247
E: czo@jtcir.com

Issuer:
Gilles R. Gagnon, M.Sc., MBA
President & CEO
T: 780-421-4555

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release 

Source: Ceapro Inc.

FINRA Says Only 14 Percent of Investors Think ESG Naturally Outperforms the Market


Image Credit: Scott (Flickr)


FINRA Survey Suggests Many ESG Investors May be Unaware Followers

 

Are ESG investors like airline passengers? A recent FINRA survey indicates, yes.

Perhaps you do this; when I get off the plane in a strange airport, I follow the crowd until I figure out where the baggage claim is. Sometimes, after a couple of minutes, I’ll ask someone that looks confident and was on my plane, where baggage is. I often find out they don’t know either; they have just been following others like me.

Survey of Investors About ESG

Gerri M. Walsh is the president of the FINRA Investor Education Foundation. Along with the NORC of the University of Chicago, they surveyed retail investors on their knowledge of Environmental, Social, and Governance (ESG) investing. Investing in funds and securities that have been designated as ESG has been a hot trend. Growth in ETFs alone has gone from $78 billion in 2019 to $378 billion earlier this year. This is a 485% increase in just over three years.

Since the trend toward investing in the ESG category is showing rampant growth, one might expect those among the herd know where they’re headed. This survey discovered instead that about one in four people believes the acronym stands for “earnings, stock, growth,” according to this well-formulated study.

 

Global Growth ESG ETF Assets from 2006 to February 2022 ($Billion)

 

Data: Statista


Survey Results

“Retail investors don’t understand ESG investing—only 9% say that they have ESG-related investments, and the familiarity with the concept is not as high or as broad as some of the coverage on the topic of ESG investing might suggest,” says Gerri Walsh.

Of the 1,228 investors surveyed, only 24% could correctly define ESG investing, and just 21% knew what the letters in ESG stood for. Walsh says this discovery is “both surprising and concerning.”

“If people are going to be thinking about these issues, we need to make sure that investors understand what we’re talking about, especially retail investors,” says FINRA’s president of investor education. “We need to make sure that people understand the terminology that’s being used, and what’s behind ESG investing.”

 

As uncovered by the survey, respondents said environmental factors were the least important when investing. The most important consideration respondents said are financial factors, including whether an investment has the potential for high returns, the related risk, and the associated fees. Perhaps the massive inflow into ESG funds has been performance-driven much more than the criteria followed by ESG funds.

The survey did, however, find that intentional ESG investors are highly motivated by ESG factors, especially the environment. When it comes to ESG funds’ performance, the greater part of investors (41%) believes that returns for companies that prioritize their impact on the environment and society will be the same as the overall market. Only 14% expect ESG investments to outperform the market.

Recent Performance Comparison

For the year 2021, a year strong year for stocks when the broader market was up 28.7% ($IVV), sustainable index funds produced similar returns. According to Morningstar data, the 13 ESG index funds available to U.S. investors that follow broad, diversified indexes of U.S. large-cap stocks posted gains ranging from 25.6% to 31.7%. Their average return was 29.2%, or 0.50% higher than the broad non-ESG specific measure.

Take-Away

There are all styles of investing. This is part of what makes markets. One conclusion that can be drawn from a recent collaboration by investment and research organizations is that ESG investors while growing in numbers, may not be intentionally investing in stocks of environmental, social, and corporate governance-minded companies. Perhaps this means investors were just following the amplified buzz around these investments. Or, it could hint that they were chasing returns that, in some cases, were running higher than the overall market.

What is now empirically shown is that only 14% believe that ESG will naturally outperform non-categorized investments. However, investing in ESG, whether intentional or not, has not been a bad move.

Paul Hoffman

Managing Editor, Channelchek

 

Suggested Reading



Issues Driving ESG Investing



What’s an ESG Score?





ESG Growing Pains Include Greenwashing



Are Small-Cap Stocks Smart Investments?

 

Sources

https://www.finra.org/about/executives/gerri-walsh

https://www.barrons.com/articles/esg-meaning-sustainable-investing-study-51649719876

https://www.morningstar.com/products/esg-investing

https://www.statista.com/topics/7463/esg-and-impact-investing/

 

Stay up to date. Follow us:

 

Synthetic Biology and a New Class of Antibiotics



Engineered Bacteria Could Help Protect “Good” Gut Microbes from Antibiotics

 

Anne Trafton | MIT
News Office

Antibiotics are life-saving drugs, but they can also harm the beneficial microbes that live in the human gut. Following antibiotic treatment, some patients are at risk of developing inflammation or opportunistic infections such as Clostridiodes difficile. Indiscriminate use of antibiotics on gut microbes can also contribute to the spread of resistance to the drugs.

In an effort to reduce those risks, MIT engineers have developed a new way to help protect the natural flora of the human digestive tract. They took a strain of bacteria that is safe for human consumption and engineered it to safely produce an enzyme that breaks down a class of antibiotics called beta-lactams. These include ampicillin, amoxicillin, and other commonly used drugs.

When this “living biotherapeutic” is given along with antibiotics, it protects the microbiota in the gut but allows the levels of antibiotics circulating in the bloodstream to remain high, the researchers found in a study of mice.

“This work shows that synthetic biology can be harnessed to create a new class of engineered therapeutics for reducing the adverse effects of antibiotics,” says James Collins, the Termeer Professor of Medical Engineering and Science in MIT’s Institute for Medical Engineering and Science (IMES) and Department of Biological Engineering, and the senior author of the new study.

Andres Cubillos-Ruiz PhD ’15, a research scientist at IMES and the Wyss Institute for Biologically Inspired Engineering at Harvard University, is the lead author of the paper, which appears today in Nature Biomedical Engineering. Other authors include MIT graduate students Miguel Alcantar and Pablo Cardenas, Wyss Institute staff scientist Nina Donghia, and Broad Institute research scientist Julian Avila-Pacheco.

Protecting the Gut

Over the past two decades, research has revealed that the microbes in the human gut play important roles in not only metabolism but also immune function and nervous system function.

“Throughout your life, these gut microbes assemble into a highly diverse community that accomplishes important functions in your body,” Cubillos-Ruiz says. “The problem comes when interventions such as medications or particular kinds of diets affect the composition of the microbiota and create an altered state, called dysbiosis. Some microbial groups disappear, and the metabolic activity of others increases. This unbalance can lead to various health issues.”

 

One major complication that can occur is infection of C. difficile, a microbe that commonly lives in the gut but doesn’t usually cause harm. When antibiotics kill off the strains that compete with C. difficile, however, these bacteria can take over and cause diarrhea and colitis. C. difficile infects about 500,000 people every year in the United States, and causes around 15,000 deaths.

Doctors sometimes prescribe probiotics (mixtures of beneficial bacteria) to people taking antibiotics, but those probiotics are usually also susceptible to antibiotics, and they don’t fully replicate the native microbiota found in the gut.

“Standard probiotics cannot compare to the diversity that the native microbes have,” Cubillos-Ruiz says. “They cannot accomplish the same functions as the native microbes that you have nurtured throughout your life.”

To protect the microbiota from antibiotics, the researchers decided to use modified bacteria. They engineered a strain of bacteria called Lactococcus lactis, which is normally used in cheese production, to deliver an enzyme that breaks down beta-lactam antibiotics. These drugs make up about 60 percent of the antibiotics prescribed in the United States.

When these bacteria are delivered orally, they transiently populate the intestines, where they secrete the enzyme, which is called beta-lactamase. This enzyme then breaks down antibiotics that reach the intestinal tract. When antibiotics are given orally, the drugs enter the bloodstream primarily from the stomach, so the drugs can still circulate in the body at high levels. This approach could also be used along with antibiotics that are injected, which also end up reaching the intestine. After their job is finished, the engineered bacteria are excreted through the digestive tract.

Using engineered bacteria that degrade antibiotics poses unique safety requirements: Beta-lactamase enzymes confer antibiotic resistance to harboring cells and their genes can readily spread between different bacteria. To address this, the researchers used a synthetic biology approach to recode the way the bacterium synthetizes the enzyme. They broke up the gene for beta-lactamase into two pieces, each of which encodes a fragment of the enzyme. These gene segments are located on different pieces of DNA, making it very unlikely that both gene segments would be transferred to another bacterial cell.

These beta-lactamase fragments are exported outside the cell where they reassemble, restoring the enzymatic function. Since the beta-lactamase is now free to diffuse in the surrounding environment, its activity becomes a “public good” for the gut bacterial communities. This prevents the engineered cells from gaining an advantage over the native gut microbes. 

“Our biocontainment strategy enables the delivery of antibiotic-degrading enzymes to the gut without the risk of horizontal gene transfer to other bacteria or the acquisition of an added competitive advantage by the live biotherapeutic,” Cubillos-Ruiz says.

Maintaining Microbial Diversity

To test their approach, the researchers gave the mice two oral doses of the engineered bacteria for every injection of ampicillin. The engineered bacteria made their way to the intestine and began releasing beta-lactamase. In those mice, the researchers found that the amount of ampicillin circulating the bloodstream was as high as that in mice who did not receive the engineered bacteria.

In the gut, mice that received engineered bacteria maintained a much higher level of microbial diversity compared to mice that received only antibiotics. In those mice, microbial diversity levels dropped dramatically after they received ampicillin. Furthermore, none of the mice that received the engineered bacteria developed opportunistic C. difficile infections, while all of the mice who received only antibiotics showed high levels of C. difficile in the gut.

“This is a strong demonstration that this approach can protect the gut microbiota, while preserving the efficacy of the antibiotic, as you’re not modifying the levels in the bloodstream,” Cubillos-Ruiz says.

The researchers also found that eliminating the evolutionary pressure of antibiotic treatment made it much less likely for the microbes of the gut to develop antibiotic resistance after treatment. In contrast, they did find many genes for antibiotic resistance in the microbes that survived in mice who received antibiotics but not the engineered bacteria. Those genes can be passed to harmful bacteria, worsening the problem of antibiotic resistance.

The researchers now plan to begin developing a version of the treatment that could be tested in people at high risk of developing acute diseases that stem from antibiotic-induced gut dysbiosis, and they hope that eventually, it could be used to protect anyone who needs to take antibiotics for infections outside the gut.

“If the antibiotic action is not needed in the gut, then you need to protect the microbiota. This is similar to when you get an X-ray, you wear a lead apron to protect the rest of your body from the ionizing radiation,” Cubillos-Ruiz says. “No previous intervention could offer this level of protection. With our new technology we can make antibiotics safer by preserving beneficial gut microbes and by reducing the chances of emergence of new antibiotic resistant variants.”

 

Suggested Reading



Opportunities in the Rapidly Growing Pain Management Sector



Stem-Cell Based Therapy for Alzheimer’s Disease





Why Stem Cell Stocks in 2021 Make Sense



Lithium Inflation and Availability Concerns Elon Musk

 

Stay up to date. Follow us:

 

Endeavour Silver (EXK)(EDR:CA) – First Quarter Production Exceeds Expectations

Tuesday, April 12, 2022

Endeavour Silver (EXK)(EDR:CA)
First Quarter Production Exceeds Expectations

As of April 24, 2020, Noble Capital Markets research on Endeavour Silver is published under ticker symbols (EXK and EDR:CA). The price target is in USD and based on ticker symbol EXK. Research reports dated prior to April 24, 2020 may not follow these guidelines and could account for a variance in the price target.

Endeavour Silver Corp is a precious metal mining company. The company is primarily engaged in silver mining and owns three high-grade, underground, silver-gold mines in Mexico. Its other business activities include acquisition, exploration, development, extraction, processing, refining and reclamation. The company is organized into four operating mining segments, Guanacevi, Bolanitos, El Cubo, and El Compas, which are located in Mexico as well as Exploration and Corporate segments. Its Exploration segment consists of projects in the exploration and evaluation phases in Mexico and Chile.

Mark Reichman, Senior Research Analyst of Natural Resources, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

    First quarter production ahead of our estimates. Compared to the prior year period, first quarter silver production increased 25% to 1,314,955 ounces, while gold production declined 22% to 8,695 ounces. We had forecast silver and gold production of 1,143,597 ounces and 8,399 ounces, respectively. The company sold 1,717,768 ounces of silver and 8,381 ounces of gold. Payable silver and gold ounces produced amounted to 1,303,540 and 8,549 ounces, respectively. Both Guanacevi and Bolanitos outperformed our forecast due to higher silver grades at both mines and higher gold grades at Guanacevi. Compared to the fourth quarter of 2021, silver and gold production declined 9% and 8%, respectively. At quarter end, Endeavour held 608,788 ounces of silver and 1,911 ounces of gold in bullion inventory and 59,594 ounces of silver and 1,931 ounces of gold in concentrate inventory.

    Updating estimates.  Our 2022 first quarter and full year EPS estimates have been increased to $0.05 and $0.15, respectively, compared to our previous estimates of $0.04 and $0.14. First quarter and full year 2022 EBITDA estimates have been raised to…


This research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision. 

Digital, Media & Entertainment Industry – Is A Recession On Investor’s Radar?

Tuesday, April 12, 2022

Digital, Media & Entertainment Industry
Is A Recession On Investor’s Radar?

Michael Kupinski, DOR, Senior Research Analyst, Noble Capital Markets, Inc.

Patrick McCann, Associate Analyst, Noble Capital Markets, Inc.

Refer to end of report for Analyst Certification & Disclosures

Overview: Is it time to buy? Consumer cyclical stocks, such as the media and entertainment sectors, tend not to perform well during periods of rising interest rates. This is a function of the sensitivity of advertising to the general economy. Rising interest rates tend to slow economic activity and potentially portend an economic downturn. For now, the fundamental environment is strong, given a robust advertising recovery that has extended into 2022.

Digital Media: High Flying Tech Stocks Get Their Wings Clipped. We highlight the MarTech sector given the significant reduction in stock valuations. Notably, one of our favorites, Harte Hanks, has withstood the bloodbath and remains an undiscovered value in this space. 

Broadcast Television: Returning Capital To Shareholders. The TV stocks outperformed the general market in the latest quarter as investors anticipate strong fundamentals in 2022, bolstered by Political. But, are there other reasons at play? We note that the stock performance is well below that of its historic averages and we find significant value in several TV plays including EVC, SSP, and GTN. 

Broadcast Radio: A Transformed IndustryThere has been a favorable transformation happening in the industry, one that is shifting away from traditional Radio and toward faster growth revenue streams, such as Digital, and, even into the Metaverse. But, investors have not taken notice. The digital transformation at Townsquare Media is one worth noting, leading our favorites in the space. 

Esports & Gaming: Can The Industry Recover? The Esports and iGaming stocks fell a significant 25% in the latest quarter, down 52% in the last 12 months. It has been a perfect storm for issues in the industry. Our focus turns toward Codere Online, a company with lots of cash to establish itself as a leader in Latin America gaming. 

Overview 

Is it time to buy? 

Consumer cyclical stocks, such as the media and entertainment sectors, tend not to perform well during periods of rising interest rates. This is a function of the sensitivity of advertising to the general economy. Rising interest rates tend to slow economic activity and potentially portend an economic downturn. The Fed Reserve indicated that it plans a series of rate hikes in 2022, with the first being a 0.25 basis point bump on March 16th. But media investors do not appear focused on the prospect of an economic downturn. This is largely due to the current favorable advertising environment. Most media companies reported better than expected advertising in the fourth quarter and guided toward favorable first quarter trends. In addition, media companies appear optimistic for the second half of the year with the anticipated influx of Political advertising. 

For this reason, we believe, the traditional media companies outperformed the S&P 500 Index in the latest quarter, with the TV sector performing the best, (highlighted later in this report). Coincidently, Broadcast Television is one of the biggest beneficiaries of the influx of Political advertising, which will largely fall in the third and fourth quarters. In addition, TV broadcasters have diversified revenue streams, most notably Retransmission Revenue, which is not tied to the vagaries of the economy. Retransmission revenues as a whole account for an average 44% of total broadcast revenue. Finally, many broadcasters indicated that sports betting has become a meaningful contributor to the improved advertising environment. With favorable revenue visibility, not surprisingly, the TV stocks have outperformed the traditional media stocks, including Broadcast Radio and Publishing. 

No doubt that there has been a rotation in the market, with investors moving toward larger, established companies, with more predictable revenue and cash flow, favoring those with solid balance sheets. A flight to quality. Developmental companies and industries that are in investment mode have struggled in this environment, like the Esports & Gaming industries. Many of these companies have investment spending desires, but may be locked out as access to the capital markets have become limited or just too expensive. As a result, many developmental companies significantly cut back costs in a survival mode reaction. Is the pain nearly over? We do not think so. In our view, while the inverted yield curve may have investors and analysts likely to begin modeling the prospect of an economic downturn in the future, we believe that the portfolio repositioning has just begun. Our key takeaway is that investors should be looking for opportunities. The best time to buy media stocks has typically been during an economic downturn or when the markets already factor one in. A process that seems to have begun. As such, we encourage investors to go hunting. We continue to favor companies that are in growth industries, have solid balance sheets, and stock valuations that may already reflect recession type valuations. Some of our favorites include Townsquare Media (TSQ), Entravision (EVC), Harte Hanks (HHS), Lee Enterprises (LEE) and Codere Online (CDRO). 

Digital Media 

High Flying Tech Stocks Get Their Wings Clipped  

As we noted last quarter, despite performing well in 2021 overall, stocks in the Internet and Digital Media sectors performed poorly in the fourth quarter of 2021.  Unfortunately, that quarter’s performance carried over into the first quarter of 2022 as Figure #1 Q1 Digital Media Stock Performance illustrates. None of Noble’s Internet and Digital Media Indices outperformed the broader market, which we define as the S&P 500.  Stocks in the S&P 500 Index decreased by 5% in 1Q 2022, which was better than Noble’s Digital Media Index (-9%), Ad Tech Index (-24%), MarTech Index (-25%), Esports & iGaming Index (-26%) and Social Media Index (-31%).      


Figure #1 Q1 Digital Media Stock Performance


Noble’s Internet & Digital Media Indices are market cap weighted, so each sector’s performance is often driven by the FAANG stocks (Facebook, Apple, Amazon, Netflix and Google).  While none of the FAANG stocks were up in the first quarter, Apple (APPL: -2%), Amazon (AMZN: -2%), and Google (GOOG: -4%) outperformed the S&P 500, while Facebook (FB: -33%), and Netflix (NFLX:  -38%) significantly underperformed the broader market.   

We attributed the 4Q 2021 underperformance in the Internet and Digital Media sectors to two factors: 1) difficult comparisons due to Covid related comparisons (i.e., companies that benefited from business migrating online in 2020 had tough comps in 4Q 2021 as the economy re-opened), and 2) the Fed pivot to signaling higher rates to tame inflation.  Both of these issues remained evident in the first quarter. 

The “re-openingâ€? story has wreaked havoc in certain stocks and sectors.  For example, investors have long been attracted to the MarTech universe based on the sector’s high growth and recurring revenue business model.  While growth has moderated slightly in recent quarters (revenues increased by 29% on average in 4Q 2021 vs. 32% in 3Q 2021), 21 of the 22 stocks in the sector posted stock price declines in 1Q 2022, and 19 of the 22 posted double digit stock price declines.  Three months ago, MarTech stocks were trading at an average revenue multiple of 8.5x and a median revenue multiple of 5.3x. Today, the “meanâ€? and median revenue multiples have fallen to 6.9x and 5.2x.  It’s interesting to note that the average multiple has contracted a lot more than the median multiple, indicating that the “high-flyingâ€? MarTech stocks have been most impacted. 

As Figure #1   Digital Media Q1 Performance illustrates, the Noble Marketing Tech Index declined 25% in the first quarter alone. A good example of the sharp re-valuation of the sector is Shopify (SHOP), which traded 22.2x 2022E revenues at the time of our last quarterly Internet and Digital Media newsletter but now trades at 12.6x 2022E revenue.  Shares of Shopify fell by 51% in the first quarter as its forward revenue multiple nearly halved.  A provider of e-commerce software, Shopify thrived during the pandemic, as many offline businesses rushed to add online storefronts. But as the economy has reopened, and more consumers return to physical retail stores, Shopify’s growth has slowed considerably.

While the activity in the sector was well pronounced in the larger cap stocks, the shares of closely followed Harte Hanks is a clear standout. The shares are largely at the same valuation as of December 31st. While the shares avoided the bloodbath of the sector, the lackluster stock performance is in spite of exceeding Q4 expectations and with estimates substantially increased for 2022 and 2023. Notably, the HHS shares also trade well below those high flyers mentioned earlier. As Figure #2 Marketing Technology Comparables illustrates, the HHS shares trade at modest multiples compared with its peers. We believe that investors have not yet caught up to the turnaround story at Harte Hanks, creating a favorable risk/reward relationship. As such, HHS is among our favorites in 2022. 

Figure #2 

High-fliers in other Internet and Digital Media sectors appear to have been more impacted by Fed policy than re-opening concerns.  In the Ad Tech sector, shares of The Trade Desk (TTD) fell by 24% during the first quarter.  Three months ago, TTD shares traded at 24.8x 2022E revenues, but today its shares trade at 18.8x 2022E revenue.  In the Social Media sector, the highest multiple stock three months ago was Snap (SNAP), which traded at 16.5x 2022E revenues, but shares of Snap fell by 24% and trade at 10.3x.  In the Digital Media sector, three months ago the highest multiple stock was Netflix, which traded at 7.3x 2022E revenues, but shares of Netflix fell by 28% and now trade at 5.3x 2022E revenue.  

It was not a great time to own shares in the Internet and Digital Media in the first quarter of 2022, despite the fact that revenue trends continue to be robust and margins continue to improve.  In our opinion, what’s changed is investor perception of where to invest in this stage of the economic cycle and the Fed’s impact as it raises rates.  While signs of a slowdown don’t appear imminent in the Internet and Digital Media sectors we monitor, investors appear concerned about the impact Fed policy will have on the sector later this year or next.  As the Fed continues to tighten monetary policy, investors appear to have rotated out of expensive, growth-oriented tech stocks and into more defensive sectors, as evidenced by the S&P Energy index increasing by +38%, the S&P Utility Index increasing by +7% and the S&P Health Care index declining by just 1%.  Each of these sectors outperformed the broader market in 1Q 2022.   

1Q 2022 M&A – Weathering the Storm; Will it Hold?   

According to S&P Global Market Intelligence, technology industry M&A slowed considerably in the first quarter of 2022 with deal value falling by 36% to $216.7 billion from $338.5 billion in the first quarter of 2021. S&P Global cites heavy M&A activity in January followed by a sharp slowdown in February and March, even though the total number of technology M&A deals increased in 1Q 2022 relative to 1Q 2021.  This is rather impressive during a quarter in which inflation reached a 40-year high, a war started in Ukraine, and publicly traded stocks performed poorly. 

Noble tracks M&A deals in a narrower subsector of technology sector, and our data showed very different trends than the broader tech M&A.  Noble breaks down our universe into 9 categories: Ad Tech; Agency & Analytics; Digital Content; Ecommerce; Information; MarTech; Mobile, and Social Media). We tracked 170 deals in these sectors in the first quarter of 2022, an 5% decrease in deal activity (unlike the broader sector).  We also did not see a material slowdown in deal activity, as we tracked 62 deals in January, 51 in February and 57 in March, which is impressive in light of inflation, a war, and stock price declines. 

The dollar value of the deals we tracked in 1Q 2022 increased by 225% to $106.8 billion, up from $32.8 billion in 1Q 2021. The huge increase comes almost solely from the $69 billion announced acquisition of Activision Blizzard by Microsoft in January.  Excluding this one transaction, deal value increased by a healthy 15% in 1Q 2002. 

From a deal volume perspective, the most active sectors we tracked were Digital Content (63 deals), Marketing Tech (47 deals) and Agency & Analytics (31 deals).  From a deal value perspective, the most active sectors were Digital Content ($86.9B), Agency & Analytics ($15.9B), Marketing Tech ($1.5B), and Ad Tech ($1.4B). 

As has been the norm for the past several quarters, the largest subsector of deal value within the Digital Content sector is the video gaming sector, with $85 billion of announced deals in the first quarter. The quarter got off to a fast start with Take-Two Interactive’s (TTWO) $12 billion announced acquisition of Zynga in early January. That was followed a little more than a week later with Microsoft’s announced acquisition of Activision Blizzard for $69 billion. Sony finished the strong January with its $3.6 billion acquisition of Bungie.  

Another sector that showed continued M&A strength was the online gaming, or “iGamingâ€? sector.  As more states and countries allow for betting online, a land rush has ensued, often times with companies buying foreign assets, where online betting has been around a while, in order to provide the tools to compete in North America, where there remains significant upside opportunity.  Some of the most notable transactions of betting software companies are provided below. We have included the Better Collective acquisition of Canada Sports Betting, even though Canada Sports Betting isn’t an online gaming company per se. Rather, we have included it because we have found that iGaming companies are targeting data and information companies which provide information to bettors, which is key to helping them understand their odds ahead of placing bets. 

In recent quarters we have written about robust M&A activity in the Digital Publishing and Podcasts sectors. However, activity in these sectors slowed considerably. In Digital Publishing, the New York Times Company announced the acquisition of sports focused content provider The Athletic for $550 million, but that was the only major digital publishing deal where the purchase price was announced publicly. In podcasting, Liberated Syndication, or Libsyn (LSYN) acquired Podcast Ad Reps for $11.9 million, but no other major podcast M&A transactions took place during the quarter. 

M&A activity weathered a storm in 1Q 2022. For now, as long as solid revenue growth, improving margins, and strong balance sheets remain the norm, we expect M&A activity to remain solid, although likely not at record levels we saw in 2021 given the backdrop of higher rates and a war on European soil, each of which creates higher levels of uncertainty. 

Esports & Gaming

Can The Industry Recover?

One of the poor performing sectors in the latest quarter was the Esports & Gaming sectors, down 25% in the quarter versus a 5% decline for the S&P 500 Index. Given the recent performance, the sector is down 52% for the trailing 12 months. The performance of the sector is disappointing given that we had expected that it would be a beneficiary of the economy reopening. Our view was that in person esports events would rebound and that igaming would become a favored way for strapped States to increase revenue. While this is still our view, we were surprised that the industry became a victim of the flight to quality. Many of the stocks in the index are developmental companies, investing to gain a foothold in the fast growing space. As such, many of the companies in the space are not cash flow positive and have needs to raise capital for investment as Figure #3 Esports/iGaming Company Comparables illustrate. With crumbling stock prices, access to the capital markets dried up. Consequently, many of these companies are in survival mode, selling non strategic assets or doing expensive capital raises, and aggressively cutting expenses. 


It has not helped that the fundamentals of some of the companies have not been as strong as expected. In the latest quarter, we have revised downward revenues and adj. EBITDA due to gaming regulations, slower than expected product rollout, and geopolitical issues. Our current favorite in the industry is Codere Online (CDRO). Codere Online currently has significant amount of cash to continue its international expansion. While the company has been adversely affected by recent gaming regulation in Spain, we believe that there is an attractive opportunity to expand into many Latin American markets. The company also has longer term plans to enter the US market. Given the significant market opportunity, the CDRO shares are among our favorites in the sector. 

Figure #3


Traditional Media

As Figure #4 Traditional Media Q1 2022 Stock Performance illustrates, the traditional media stocks outperformed the general market in the latest quarter as measured by the S&P 500 Index, with the strongest sector being Broadcast Television, up slightly over 15% versus a 5% decline by the general market. Our following comments on the Traditional Media stocks are broken down into Broadcast TV, Broadcast Radio, and Publishing.

Figure #4 Traditional Media Q1 2022 Stock Performance


Broadcast Television: Returning Capital To Shareholders

The Noble Broadcast TV index increased 15% in the first quarter as investors anticipate a strong fundamental year in 2022 with the influx of Political advertising and a strong economy. Some broadcasters indicated that Political advertising in 2022 could be more than what was spent in the past Presidential election year. We are not as sanguine about that opportunity, but believe that Political advertising should increase a solid 30%, which is in line with the historic 20 year growth rates over Presidential year and biennial election year cycles. While the key auto category is still not fully recovered, broadcast management indicated that the category should cycle toward growth in 2023, a function of supply chain issues abating and a significant number of new models being introduced. Notably, most companies appeared very optimistic about sports betting advertising, which has emerged to become a leading category. Several large States appear to be poised to approve online sports betting, like Florida and California, which should meaningfully bolster core advertising.

In addition, we believe the reason that the stocks outperformed in the quarter, investors have come to realize that advertising is a smaller portion of total broadcast revenue. For the year 2021, Retransmission revenue, a stable a predictable source of revenue, now accounts for a significant 44% of average broadcast revenue. Finally, the broadcast industry has substantially improved balance sheets.  Industry wide, net debt is on average 3.6 times EBITDA, with the mean at a modest 2.7 times. While there are companies higher than the averages, many of those companies have a path toward lowered leverage in 2022 given the anticipate influx of high margin Political advertising.

With the favorable fundamental tailwind and reasonable debt levels, many companies are returning capital to shareholders in the form of dividends and share repurchase programs. Entravision announced a $20 million share repurchase program and Nexstar increased its quarterly cash dividend by 29%. We believe that more companies are likely to announce similar moves as debt leverage comes down. 

Notably, with the favorable Q1 stock performance up 15%, the Noble Broadcast TV index over the trailing 12 months increased a modest 1%. This modest gain was below historic 25 year averages for the stocks in the year prior to an election year. On average, TV stock gained 22% in the year prior to an election year. We wonder if investors are nervous about the geopolitical events, rising inflation and rising interest rates. Notably, the stock valuations appear compelling. As Figure #5 Broadcast TV Company Comparables illustrate, the average TV stock trades at 6.5 times EV to 2022 EBITDA and 7.5 times 2023 EBITDA, at the low end of historic averages in the range of 6 to 12 times. In our view, the Broadcast TV stocks appear to trade at recessionary type valuations. As such, we believe that investors should go hunting for bargains in TV. Our favorites include Entravision (EVC), E.W. Scripps (SSP), and Gray Television (GTN). One note on Entravision, the company has significantly transitioned to a Digital Media company through a series of well-timed acquisitions. As we noted in the Marketing Tech section of this report, the average of those stocks trade at 4.2 times revenues. Making adjustments for the gross Digital revenues, the value for its Digital Media business would be $512 million, more than the entire market cap of the company. 

Figure #5  



Broadcast Radio: A Transformed Industry

The Broadcast Radio stocks failed to hold onto the previous quarter gains and fell in line with the general market in the first quarter 2022, down slightly over 4%. For the trailing 12 months, the Radio stocks were flat versus a 15% gain for the general market, as measured by the S&P 500 Index. The relatively poor performance of the Radio group, in our view, does not do the group justice. 

There has been a favorable transformation happening in the industry, one that is shifting away from traditional Radio and toward faster growth revenue streams, such as Digital, and, even into the Metaverse. In addition, many companies are aggressively paring down debt, another aspect we believe is missed by investors. Furthermore, there is a favorable fundamental tailwind, bolstered by strong revenue growth in developing ad categories including Crypto Currency and Sports Betting. And, there is improving trends in the important Auto category. In addition, the industry is expected to benefit from the influx of Political advertising, largely in the fourth quarter. Political advertising typically accounts for roughly 3% of total full year Radio revenue. 

Regarding the transformation…Many of the Radio broadcasters have invested in growing businesses outside of Radio and into fast growing Digital, podcasts, esports, and gaming. For some of the more aggressive diversified Radio companies, like Salem Media and Townsquare Media, Digital now accounts for 29% and 50% of total company revenues, respectively. Beasley Broadcasting, with Digital roughly 13% of total revenues, is ramping up its Digital investments, which is expected to reflect an acceleration in revenue and improved margins. Companies like iHeart Media have even announced venturing into the Metaverse to bring virtual spaces and enhanced fan experiences. Importantly, Digital revenue streams have been especially resilient during the Covid pandemic and we would expect a similar experience should the economy weaken. 

Debt is coming down…Companies like Cumulus Media, Salem Media and Beasley Broadcasting, which have had some of the highest debt leverage in the industry, have shored up balance sheets through asset sales and aggressive debt reduction. In the case of Cumulus, management highlighted that debt levels are approaching a range that it will likely pursue some form of a return of capital to shareholders. This prospect seemed to be dismissed by investors, the CMLS shares are down 30% from highs reached in November 2021. 

As Figure #6 illustrates, the Radio stocks trade at compelling multiples below 7 times EV to EBITDA. Notably, some of these companies have significant Digital Media operations, and, as such, the stock valuations are all the more compelling. For instance, as illustrated earlier in the Digital Media section of this report, the Digital Marketing Technology stocks trade an average 4.2 times Enterprise Value to Revenues. Applying this metric to Townsquare’s Digital businesses would place a stock valuation at $35 per share. That would be just for its Digital businesses! We believe that investors have not yet realized the transformation of some of these companies, or the substantial upside as these companies garner more attractive valuations based on its fast growing businesses lines. Townsquare Media is among our favorites in the Radio sector. 

Figure #6  


Publishing

The Noble Publishing Index was down a modest 3% in the first quarter, slightly outperforming the general market’s 5% decline. For the latest 12 months, the Noble Publishing Index decline 11%, underperforming the general market’s 14% advance. The biggest news in the Publishing sector was that Lee Enterprises successfully thwarted the Alden Group’s efforts to gain seats on the company’s board and take control of the company. Notably, near current levels, the LEE shares trade slightly above the $24 takeover offer by the Alden Group. We believe that the recent weakness in the shares, down from recent highs in January of $43, is a reflection of investors exiting the takeover story. 

While deal oriented investors appear to be putting pressure on the LEE shares, we encourage investors to take a look at this company. The company is aggressively investing into its Digital future and is near the transition toward revenue growth. We believe that the company’s favorable revenue and cash flow growth outlook into 2024 is compelling as highlighted in Figure #7 Newspaper Industry Comparables. The LEE shares have a favorable risk/reward relationship and one of the most aggressive price targets of $50 per share. As such, the LEE shares are among our favorites in the media sector. 

Figure #7 

Companies mentioned in the report:

Beasley Broadcast Group

Codere Online

Cumulus Media

Entravision

E.W. Scripps

Gray Television

Harte Hanks

Lee Enterprises

Salem Media Group

Townsquare Media


GENERAL DISCLAIMERS

All statements or opinions contained herein that include the words “we”, “us”, or “our” are solely the responsibility of Noble Capital Markets, Inc.(“Noble”) and do not necessarily reflect statements or opinions expressed by any person or party affiliated with the company mentioned in this report. Any opinions expressed herein are subject to change without notice. All information provided herein is based on public and non-public information believed to be accurate and reliable, but is not necessarily complete and cannot be guaranteed. No judgment is hereby expressed or should be implied as to the suitability of any security described herein for any specific investor or any specific investment portfolio. The decision to undertake any investment regarding the security mentioned herein should be made by each reader of this publication based on its own appraisal of the implications and risks of such decision.

This publication is intended for information purposes only and shall not constitute an offer to buy/sell or the solicitation of an offer to buy/sell any security mentioned in this report, nor shall there be any sale of the security herein in any state or domicile in which said offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or domicile. This publication and all information, comments, statements or opinions contained or expressed herein are applicable only as of the date of this publication and subject to change without prior notice. Past performance is not indicative of future results.

Noble accepts no liability for loss arising from the use of the material in this report, except that this exclusion of liability does not apply to the extent that such liability arises under specific statutes or regulations applicable to Noble. This report is not to be relied upon as a substitute for the exercising of independent judgement. Noble may have published, and may in the future publish, other research reports that are inconsistent with, and reach different conclusions from, the information provided in this report. Noble is under no obligation to bring to the attention of any recipient of this report, any past or future reports. Investors should only consider this report as single factor in making an investment decision.

IMPORTANT DISCLOSURES

This publication is confidential for the information of the addressee only and may not be reproduced in whole or in part, copies circulated, or discussed to another party, without the written consent of Noble Capital Markets, Inc. (“Noble”). Noble seeks to update its research as appropriate, but may be unable to do so based upon various regulatory constraints. Research reports are not published at regular intervals; publication times and dates are based upon the analyst’s judgement. Noble professionals including traders, salespeople and investment bankers may provide written or oral market commentary, or discuss trading strategies to Noble clients and the Noble proprietary trading desk that reflect opinions that are contrary to the opinions expressed in this research report.

The majority of companies that Noble follows are emerging growth companies. Securities in these companies involve a higher degree of risk and more volatility than the securities of more established companies. The securities discussed in Noble research reports may not be suitable for some investors and as such, investors must take extra care and make their own determination of the appropriateness of an investment based upon risk tolerance, investment objectives and financial status.

Company Specific Disclosures

The following disclosures relate to relationships between Noble and the company (the “Company”) covered by the Noble Research Division and referred to in this research report.

Noble is not a market maker in any of the companies mentioned in this report. Noble intends to seek compensation for investment banking services and non-investment banking services (securities and non-securities related) with any or all of the companies mentioned in this report within the next 3 months

ANALYST CREDENTIALS, PROFESSIONAL DESIGNATIONS, AND EXPERIENCE

Director of Research. Senior Equity Analyst specializing in Media & Entertainment. 34 years of experience as an analyst. Member of the National Cable Television Society Foundation and the National Association of Broadcasters. BS in Management Science, Computer Science Certificate and MBA specializing in Finance from St. Louis University.

Named WSJ ‘Best on the Street’ Analyst six times.

FINRA licenses 7, 24, 66, 86, 87

WARNING

This report is intended to provide general securities advice, and does not purport to make any recommendation that any securities transaction is appropriate for any recipient particular investment objectives, financial situation or particular needs. Prior to making any investment decision, recipients should assess, or seek advice from their advisors, on whether any relevant part of this report is appropriate to their individual circumstances. If a recipient was referred to Noble Capital Markets, Inc. by an investment advisor, that advisor may receive a benefit in respect of transactions effected on the recipients behalf, details of which will be available on request in regard to a transaction that involves a personalized securities recommendation. Additional risks associated with the security mentioned in this report that might impede achievement of the target can be found in its initial report issued by Noble Capital Markets, Inc.. This report may not be reproduced, distributed or published for any purpose unless authorized by Noble Capital Markets, Inc.

RESEARCH ANALYST CERTIFICATION

Independence Of View
All views expressed in this report accurately reflect my personal views about the subject securities or issuers.

Receipt of Compensation
No part of my compensation was, is, or will be directly or indirectly related to any specific recommendations or views expressed in the public
appearance and/or research report.

Ownership and Material Conflicts of Interest
Neither I nor anybody in my household has a financial interest in the securities of the subject company or any other company mentioned in this report.

NOBLE RATINGS DEFINITIONS % OF SECURITIES COVERED % IB CLIENTS
Outperform: potential return is >15% above the current price 94% 32%
Market Perform: potential return is -15% to 15% of the current price 7% 4%
Underperform: potential return is >15% below the current price 0% 0%

NOTE: On August 20, 2018, Noble Capital Markets, Inc. changed the terminology of its ratings (as shown above) from “Buy” to “Outperform”, from “Hold” to “Market Perform” and from “Sell” to “Underperform.” The percentage relationships, as compared to current price (definitions), have remained the same.

Additional information is available upon request. Any recipient of this report that wishes further information regarding the subject company or the disclosure information mentioned herein, should contact Noble Capital Markets, Inc. by mail or phone.

Noble Capital Markets, Inc.
150 East Palmetto Park Rd., Suite 110
Boca Raton, FL 33432
561-994-1191

Noble Capital Markets, Inc. is a FINRA (Financial Industry Regulatory Authority) registered broker/dealer.
Noble Capital Markets, Inc. is an MSRB (Municipal Securities Rulemaking Board) registered broker/dealer.
Member – SIPC (Securities Investor Protection Corporation)

Report ID: 24375

Release – Comstock Announces LiNiCo’s New President



Comstock Announces LiNiCo’s New President

Research, News, and Market Data on Comstock Mining

VIRGINIA CITY, NEVADA, APRIL 12, 2022 – Comstock Mining Inc. (NYSE: LODE) (“Comstock” and the “Company”) today announced the appointment of Leonardo Riera, as president of LINICO Corporation, its electrification products subsidiary, located in the Tahoe Reno Industrial Center, Nevada.  

Mr. Riera is an experienced chief executive, with global experience in the renewable energy, manufacturing, mergers and acquisition, capital markets and financial services industries. Mr. Riera spent a decade as the Executive Director and Country Head for Bankers Trust Company in Venezuela, overseeing all of their investment banking and broker-dealer operations. Mr. Riera was the founder and chief executive office of an engineering-centric, clean waste-to-energy company with projects in three countries. Mr. Riera was also the Asset Director for a multi-billion-dollar Emerging Markets fund, where he oversaw capital deployment in over fifteen emerging international markets. Mr. Riera started his career as a consultant for McKinsey & Co., working with clients such as Citicorp Investment Bank – Brazil, and subsequently proceeded to head their regional Mergers & Acquisitions unit.
 

Mr. Riera is a graduate of Andres Bello Catholic University, Caracas, Venezuela (B.S. in Economics) and of the University of Pennsylvania’s Wharton School of Business (M.B.A in Finance and International Management). Mr. Riera is fluent in English and Spanish and a frequent global speaker to leaders on renewable energies and their positive environmental and social impacts.
 

“Leo is a seasoned executive with multiple, rapid revenue start up and industry consolidation experience, who quickly moved to Reno and immediately established himself within the LiNiCo team, where he is fully dedicated and already implementing LiNiCo’s strategic plan. His knowledge of supply chains, markets, renewable energy, finance and the capital markets will accelerate LiNiCo’s growth.  We have been working together daily for the past two weeks and thrilled to have Leo on board and fully committed to LiNiCo’s and its success,” stated Mr. Corrado De Gasperis, Executive Chairman and CEO. 
 

The Company’s 2022 AGM has been scheduled for Thursday, May 26, 2022, at 9:00 a.m. PDT in Reno, Nevada, at the Atlantis Hotel. The meeting will feature Comstock’s renewable businesses and highlight the Company’s expanded senior management teams, including Mr. Riera, and the Company’s directors.

About Comstock 
Comstock (NYSE: LODE) innovates technologies that enable systemic decarbonization and circularity by efficiently converting under-utilized waste and renewable natural resources into fuels and electrification products that contribute to balancing global uses and emissions of carbon. Comstock plans to achieve extraordinary financial, natural, and social gains by building, owning, and operating a fleet of advanced carbon neutral extraction and refining facilities, commercializing complimentary process solutions and related services, and licensing selected technologies to strategic partners.
 

To learn more, please visit www.comstock.inc.
 

Forward-Looking Statements
This press release and any related calls or discussions may include forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements, other than statements of historical facts, are forward-looking statements. The words “believe,” “expect,” “anticipate,” “estimate,” “project,” “plan,” “should,” “intend,” “may,” “will,” “would,” “potential” and similar expressions identify forward-looking statements, but are not the exclusive means of doing so. Forward-looking statements include statements about matters such as: future industry market conditions; future explorations or acquisitions; future changes in our exploration activities; future changes in our research and development; and future prices and sales of, and demand for, our products and services. Except as may be required by securities or other law, we undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise.
 

Neither this press release nor any related call or discussion constitutes an offer to sell, the solicitation of an offer to buy or a recommendation with respect to any securities of the Company, the fund or any other issuer.

Release – Tonix Pharmaceuticals to Participate in the NobleCon18 Investor Conference



Tonix Pharmaceuticals to Participate in the NobleCon18 Investor Conference

Research, News, and Market Data on Tonix Pharmaceuticals

CHATHAM, N.J., April 12, 2022 (GLOBE NEWSWIRE) — Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP), a clinical-stage biopharmaceutical company, announced today that Seth Lederman, President and Chief Executive Officer of Tonix Pharmaceuticals, will present and conduct investor meetings at NobleCon18, Noble Capital Markets’ Eighteenth Annual In-Person Small & Microcap Investor Conference being held April 19-21, 2022, in Hollywood, Florida.

Details of the Tonix Pharmaceuticals Presentation

Event

NobleCon18, Noble Capital Markets’ Eighteenth Annual In-Person Small & Microcap Investor Conference

Date

Thursday, April 21

Time

9:30 a.m. ET

Location

Hard Rock Hotel & Casino, Hollywood, Florida

Track

Seminole Ballroom C

A webcast of the Company’s presentation will be available under the IR Events tab of the Tonix website at www.tonixpharma.com starting April 22.   

About Tonix
Pharmaceuticals Holding Corp.

Tonix is a clinical-stage biopharmaceutical company focused on discovering, licensing, acquiring and developing therapeutics and diagnostics to treat and prevent human disease and alleviate suffering. Tonix’s portfolio is composed of immunology, rare disease, infectious disease, and central nervous system (CNS) product candidates. Tonix’s immunology portfolio includes biologics to address organ transplant rejection, autoimmunity and cancer, including TNX-1500which is a humanized monoclonal antibody targeting CD40-ligand being developed for the prevention of allograft and xenograft rejection and for the treatment of autoimmune diseases. A Phase 1 study of TNX-1500 is expected to be initiated in the second half of 2022. Tonix’s rare disease portfolio includes TNX-29002 for the treatment of Prader-Willi syndrome. TNX-2900 has been granted Orphan-Drug Designation by the FDA. Tonix’s infectious disease pipeline includes a vaccine in development to prevent smallpox and monkeypox called TNX-8013, next-generation vaccines to prevent COVID-19, an antiviral to treat COVID-19, and a potential treatment for Long COVID. Tonix’s lead vaccine candidates for COVID-19 are TNX-1840 and TNX-18504, which are live virus vaccines based on Tonix’s recombinant pox vaccine (RPV) platform. TNX-3500
5 (sangivamycin, i.v. solution) is a small molecule antiviral drug to treat acute COVID-19 and is in the pre-IND stage of development. TNX-102 SL6, (cyclobenzaprine HCl sublingual tablets), is a small molecule drug being developed to treat Long COVID, a chronic post-COVID condition. Tonix expects to initiate a Phase 2 study in Long COVID in the first half of 2022. The Company’s CNS portfolio includes both small molecules and biologics to treat pain, neurologic, psychiatric and addiction conditions. Tonix’s lead CNS candidate, TNX-102 SL, is in mid-Phase 3 development for the management of fibromyalgia with a new Phase 3 study expected to start in the first half of 2022. Finally, TNX-13007 is a biologic designed to treat cocaine intoxication that is expected to start a Phase 2 trial in the first half of 2022.

1TNX-1500 is an
investigational new biologic at the pre-IND stage of development and has not
been approved for any indication.

2TNX-2900 is an
investigational new drug at the pre-IND stage of development and has not been
approved for any indication.

3TNX-801 is a
live horsepox virus vaccine for percutaneous administration in development to
protect against smallpox and monkeypox. TNX-801 is an investigational new
biologic and has not been approved for any indication.

4TNX-1840 and
TNX-1850 are live horsepox virus vaccines for percutaneous administration, in
development to protect against COVID-19. TNX-1840 and TNX-1850 are designed to
express the SARS-CoV-2 spike protein from the omicron and BA.2 variants,
respectively. TNX-1840 and TNX-1850 are investigational new biologics at the
pre-IND stage of development and have not been approved for any
indication. 

5TNX-3500 is an
investigational new drug at the pre-IND stage of development and has not been
approved for any indication.

6TNX-102 SL is
an investigational new drug and has not been approved for any indication.

7TNX-1300 is an
investigational new biologic and has not been approved for any indication.

This press release and further information about Tonix can be found at www.tonixpharma.com.

Forward
Looking Statements

Certain statements in this press release are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995. These statements may be identified by the use of forward-looking words such as “anticipate,” “believe,” “forecast,” “estimate,” “expect,” and “intend,” among others. These forward-looking statements are based on Tonix’s current expectations and actual results could differ materially. There are a number of factors that could cause actual events to differ materially from those indicated by such forward-looking statements. These factors include, but are not limited to, risks related to the failure to obtain FDA clearances or approvals and noncompliance with FDA regulations; delays and uncertainties caused by the global COVID-19 pandemic; risks related to the timing and progress of clinical development of our product candidates; our need for additional financing; uncertainties of patent protection and litigation; uncertainties of government or third party payor reimbursement; limited research and development efforts and dependence upon third parties; and substantial competition. As with any pharmaceutical under development, there are significant risks in the development, regulatory approval and commercialization of new products. Tonix does not undertake an obligation to update or revise any forward-looking statement. Investors should read the risk factors set forth in the Annual Report on Form 10-K for the year ended December 31, 2021, as filed with the Securities and Exchange Commission (the “SEC”) on March 14, 2022, and periodic reports filed with the SEC on or after the date thereof. All of Tonix’s forward-looking statements are expressly qualified by all such risk factors and other cautionary statements. The information set forth herein speaks only as of the date thereof.

Contacts

Jessica Morris (corporate)
Tonix Pharmaceuticals
investor.relations@tonixpharma.com
(862) 799-8599

Olipriya Das, Ph.D. (media)
Russo Partners
Olipriya.Das@russopartnersllc.com
(646) 942-5588

Peter Vozzo (investors)
ICR Westwicke
peter.vozzo@westwicke.com
(443) 213-0505

 

Source: Tonix Pharmaceuticals Holding Corp.

Release – electroCore Provides Business Update and Select First Quarter 2022 Financial Guidance



electroCore Provides Business Update and Select First Quarter 2022 Financial Guidance

News and Market Data on electroCore

April 12, 2022 at 8:00 AM EDT

  • Record revenue
    from product sales will be approximately $1.9M;
    approximately 60% growth over first quarter 2021
  • March 31, 2022,
    cash balance of approximately $29.9M

ROCKAWAY, N.J.

April 12, 2022 (GLOBE NEWSWIRE) — 
electroCore, Inc.
 (the “Company”) (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today provided an operating and business update as well as select unaudited preliminary financial guidance for the first quarter of 2022.

“We are pleased to announce preliminary first quarter results, recording approximately 60% growth over same period last year, and approximately 27% growth over the fourth quarter of 2021,” stated  Dan Goldberger , Chief Executive Officer of electroCore. “Revenue from product sales in the quarter ended 
March 31, 2022, will be approximately 
$1.9 million
. This is the second consecutive quarter where our total revenue growth over the prior year quarter was approximately 60% indicating that our continued investment in our sales channels and marketing initiatives are expanding consumer awareness and building momentum into the remainder of 2022.” 

Government
Channels:
 During the first quarter of 2022, the Company expects to recognize revenue of approximately 
$1,260,000 pursuant to the 
Department of Veterans Affairs (“VA”) and 
Department of Defense (“DoD”) originating prescriptions, compared to 
$858,000 or 47% growth from the fourth quarter of 2021 and 
$679,000 or 86% growth over the first quarter of 2021. 105 
VA and 
DoD military treatment facilities have purchased gammaCore products through 
March 31, 2022, as compared to 100 through the fourth quarter of 2021 and 79 through the first quarter of 2021.

Commercial: During the first quarter of 2022, the Company expects to recognize revenue of approximately 
$300,000 from our commercial channels, dominated by our cash pay initiatives and representing approximately an 11% increase over Q4 2021 and a 107% increase from Q1 2021.

Outside
of the U.S.:
 The Company expects to recognize revenue of approximately 
$300,000 outside of the 
U.S. for the first quarter ended 
March 31, 2022
, representing approximately 15% decrease from Q4 2021 and 20% decrease from Q1 2021. Our international business was impacted by COVID in January and February of this year, but the channel started to rebound in 
March 2022
.

Financial
Guidance

Preliminary unaudited financial guidance for the first quarter of 2022:

Revenue: The Company anticipates first quarter 2021 revenue from product sales will be approximately 
$1.9 million. This represents an approximately 27% increase over fourth quarter 2021 revenue of 
$1.5 million and approximately 60% growth over first quarter 2021 revenue of 
$1.2 million
.

Cash
Position: 
The Company ended the first quarter of 2022 with approximately 
$29.9 million
 of cash, cash equivalents, and marketable securities, compared to 
$34.7 million as of the end of 2021. 

Mr. Goldberger  further commented, “Our business grew robustly in the first quarter, despite the headwinds faced overseas as a result of COVID. With our strong balance sheet and discipline around targeted investment in sales and marketing, we will be able to educate and improve physician and patient awareness, which will ultimately lead to the successful adoption of gammaCore globally.”

The Company intends to provide a detailed operational and financial update during its first quarter of 2022 earnings call in 
May 2022
.

About
electroCore, Inc.

electroCore, Inc. is a commercial stage bioelectronic medicine company dedicated to improving patient outcomes through its non-invasive vagus nerve stimulation therapy platform, initially focused on the treatment of multiple conditions in neurology. The company’s current indications are the preventive treatment of cluster headache and migraine, the acute treatment of migraine and episodic cluster headache, the acute and preventive treatment of migraines in adolescents, and paroxysmal hemicrania and hemicrania continua in adults.

For more information, visit www.electrocore.com.

About
gammaCore™

gammaCore™ (nVNS) is the first non-invasive, hand-held medical therapy applied at the neck to treat migraine and cluster headache through the utilization of a mild electrical stimulation to the vagus nerve that passes through the skin. Designed as a portable, easy-to-use technology, gammaCore is self-administered by patients, as needed, without the potential side effects associated with commonly prescribed drugs. When placed on a patient’s neck over the vagus nerve, gammaCore stimulates the nerve’s afferent fibers, which may lead to a reduction of pain in patients.

gammaCore (nVNS) is FDA cleared in 
the United States for adjunctive use for the preventive treatment of cluster headache in adult patients, the acute treatment of pain associated with episodic cluster headache in adult patients, and the acute and preventive treatment of migraine in adolescent (ages 12 and older) and adult patients, and paroxysmal hemicrania and hemicrania continua in adult patients. gammaCore is CE-marked in the 
European Union for the acute and/or prophylactic treatment of primary headache (Migraine, Cluster Headache, Trigeminal Autonomic Cephalalgias and Hemicrania Continua) and Medication Overuse Headache in adults.

gammaCore is contraindicated for patients if they:

  • Have an active implantable medical device, such as a pacemaker, hearing aid implant, or any implanted electronic device
  • Have a metallic device, such as a stent, bone plate, or bone screw, implanted at or near the neck
  • Are using another device at the same time (e.g., TENS Unit, muscle stimulator) or any portable electronic device (e.g., mobile phone)

Safety and efficacy of gammaCore have not been evaluated in the following patients:

  • Adolescent patients with congenital cardiac issues
  • Patients diagnosed with narrowing of the arteries (carotid atherosclerosis)
  • Patients who have had surgery to cut the vagus nerve in the neck (cervical vagotomy)
  • Pediatric patients (less than 12 years)
  • Pregnant women
  • Patients with clinically significant hypertension, hypotension, bradycardia, or tachycardia

For more information, please visit gammaCore.com.

Forward-Looking
Statements

This press release may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements include, but are not limited to, statements about electroCore’s expectations for revenue and cash used in operations during the first quarter 2022, growth through acquisitions, its expectations for future performance, as well as electroCore’s business prospects (including its e-commerce initiative, and gConcierge and gCDirect programs) and clinical and product development plans for 2022 and beyond, its pipeline or potential markets (including cash pay programs) for its technologies, additional indications for gammaCore, the timing, outcome and impact of regulatory, clinical and commercial developments (including human trials for the study of headache, PTH, mTBI, Parkinson’s diseases and sleep deprivation stress and the business, operating or financial impact of such studies), further international expansion, and statements about anticipated distribution arrangements, government and payor funding arrangements (including those relating to 
Canada
Western Europe

Qatar
Taiwan, and 
China) and other statements that are not historical in nature, particularly those that utilize terminology such as “anticipates,” “will,” “expects,” “believes,” “intends,” other words of similar meaning, derivations of such words and the use of future dates. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, the ability to raise the additional funding needed to continue to pursue electroCore’s business and product development plans, the inherent uncertainties associated with developing new products or technologies, the ability to commercialize gammaCore™, competition in the industry in which electroCore operates and overall market conditions. Any forward-looking statements are made as of the date of this press release, and electroCore assumes no obligation to update the forward-looking statements or to update the reasons why actual results could differ from those projected in the forward-looking statements, except as required by law. Investors should consult all of the information set forth herein and should also refer to the risk factor disclosure set forth in the reports and other documents electroCore files with the 
SEC available at 
www.sec.gov.

Contact: Rich Cockrell CG Capital
404-736-3838
ecor@cg.capital

 

Release – Cocrystal Pharma Reports Favorable Preliminary Data from Phase 1 Initial Cohorts with CC-42344, a Novel, Broad-Spectrum Influenza A antiviral



Cocrystal Pharma Reports Favorable Preliminary Data from Phase 1 Initial Cohorts with CC-42344, a Novel, Broad-Spectrum Influenza A antiviral

Research, News, and Market Data on Cocrystal Pharma

CC-42344 administered
orally as a single 100 mg or 200 mg dose in healthy adults showed a
favorable safety and pharmacokinetic profile

BOTHELL, Wash., April
12, 2022 (GLOBE NEWSWIRE) — 
Cocrystal Pharma, Inc. (Nasdaq: COCP) (“Cocrystal” or the “Company”) reported preliminary results of a Phase 1 study with CC-42344, demonstrating a favorable safety and pharmacokinetic profile. CC-42344 is a broad-spectrum oral antiviral for the treatment of pandemic and seasonal influenza A with a novel mechanism of action.

The ongoing Phase 1 clinical trial plans to enroll 56 healthy adults. Results from the first two single-ascending dose 100 mg and 200 mg cohorts showed a favorable pharmacokinetic profile of CC-42344. To date, CC-42344, has demonstrated excellent oral bioavailability, dose-dependent plasma exposures, and a half-life supportive of oral daily dosing. The Phase 1 study is designed to evaluate CC-42344 administered in single-ascending and multiple-ascending doses. Cocrystal expects to report full results from the study in 2022.

“Today’s update reinforces Cocrystal’s progress in developing best-in-class antiviral medicines. Influenza is one of the most serious worldwide public health threats. Important concerns remain about the emergence of pandemic strains and resistance to available drugs. We are encouraged by the safety and pharmacokinetic profile observed to date with single oral doses of CC-42344 and look forward to initiating the next portion of the trial,” said Sam Lee, Ph.D., Cocrystal’s President and co-interim CEO. “Based on a novel mechanism of action and high barrier to resistance, we believe CC-42344 could provide a potentially best-in-class oral candidate for the treatment of pandemic and seasonal influenza infection.”

About CC-42344
CC-42344 is an oral PB2 inhibitor that blocks an essential step of viral replication and was discovered using Cocrystal’s proprietary structure-based drug discovery platform technology. It is specifically designed to be effective against all significant pandemic and seasonal influenza A strains and to have a high barrier to resistance due to the way the virus’ replication machinery is targeted. CC-42344 targets the influenza polymerase, an essential replication enzyme with several highly essential regions common to multiple influenza strains, including pandemic strains. In vitro testing showed CC-42344’s excellent antiviral activity against influenza A strains, including pandemic and seasonal strains, as well as against strains resistant to Tamiflu® and Xofluza, while also demonstrating favorable pharmacokinetic and safety profiles.

About Cocrystal
Pharma, Inc.

Cocrystal Pharma, Inc. is a clinical-stage biotechnology company discovering and developing novel antiviral therapeutics that target the replication process of influenza viruses, coronaviruses (including SARS-CoV-2), hepatitis C viruses and noroviruses. Cocrystal employs unique structure-based technologies and Nobel Prize-winning expertise to create first- and best-in-class antiviral drugs. For further information about Cocrystal, please visit www.cocrystalpharma.com.

Cautionary Note
Regarding Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding our plans to enroll 56 new subjects for the Company’s influenza A Phase 1 study, expectations of reporting full results of the study later in 2022, and the potential of CC-42344 to be a best-in-class candidate for the treatment of seasonal and pandemic influenza. The words “believe,” “may,” “estimate,” “continue,” “anticipate,” “intend,” “should,” “plan,” “could,” “target,” “potential,” “is likely,” “will,” “expect” and similar expressions, as they relate to us, are intended to identify forward-looking statements. We have based these forward-looking statements largely on our current expectations and projections about future events. Some or all of the events anticipated by these forward-looking statements may not occur. Important factors that could cause actual results to differ from those in the forward-looking statements include, but are not limited to, the risks and uncertainties arising from any future impact of the COVID-19 pandemic and the Russian invasion of Ukraine on the Australian and global economy and on our Company, including supply chain disruptions and our continued ability to proceed with our programs, including our influenza A program, the ability of the contract research organization to recruit patients into clinical trials, the results of future preclinical and clinical studies, and general risks arising from clinical trials. Further information on our risk factors is contained in our filings with the SEC, including our Annual Report on Form 10-K for the year ended December 31, 2021. Any forward-looking statement made by us herein speaks only as of the date on which it is made. Factors or events that could cause our actual results to differ may emerge from time to time, and it is not possible for us to predict all of them. We undertake no obligation to publicly update any forward-looking statement, whether as a result of new information, future developments or otherwise, except as may be required by law.

Investor Contact:
LHA Investor Relations
Jody Cain
310-691-7100

jcain@lhai.com

Media Contact:
JQA Partners
Jules Abraham
917-885-7378

Jabraham@jqapartners.com

Source: Cocrystal Pharma, Inc.

Release – Ocugen, Inc. Provides Update on its Phase 2/3 Study of COVAXIN (BBV152)



Ocugen, Inc. Provides Update on its Phase 2/3 Study of COVAXIN™ (BBV152)

Research, News, and Market Data on Ocugen

MALVERN, Pa., April 12, 2022 (GLOBE NEWSWIRE) — Ocugen, Inc. (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene therapies, biologicals and vaccines, announced that the Company was informed by the U.S. Food and Drug Administration (FDA) that the agency placed its Phase 2/3 immuno-bridging and broadening study for COVAXIN™ (BBV152), OCU-002, on clinical hold.  This is a result of the Company’s decision to voluntarily implement a temporary pause in dosing participants of OCU-002 while it evaluates statements made by the World Health Organization following their inspection of Bharat Biotech International Limited’s (BBIL) manufacturing facility. We will work with the FDA to address any questions.

About
Ocugen, Inc.

Ocugen, Inc. is a biotechnology company focused on discovering, developing, and commercializing novel gene therapies, biologicals and vaccines that improve health and offer hope for people and global communities. We are making an impact through courageous innovation, taking science in new directions in service of patients. Our breakthrough modifier gene therapy platform has the potential to treat multiple diseases with one drug and we are advancing research in other therapeutic areas to offer new options for people with unmet medical needs. Discover more at www.ocugen.com and follow us on Twitter and LinkedIn.

Cautionary
Note on Forward-Looking Statements

This press release contains forward-looking statements
within the meaning of The Private Securities Litigation Reform Act of 1995,
which are subject to risks and uncertainties. Such forward-looking statements
within this press release include, without limitation, our intent to work
closely with the FDA with respect to resolving the clinical hold on our immune
bridging trial for COVAXIN™. We may, in some cases, use terms such as
“predicts,” “believes,” “potential,” “proposed,” “continue,” “estimates,”
“anticipates,” “expects,” “plans,” “intends,” “may,” “could,” “might,” “will,”
“should,” or other words that convey uncertainty of future events or outcomes
to identify these forward-looking statements. Such statements are subject to
numerous important factors, risks and uncertainties that may cause actual
events or results to differ materially from our current expectations, such as
market and other conditions. These and other risks and uncertainties are more
fully described in our periodic filings with the Securities and Exchange
Commission (the “SEC”), including the risk factors described in the section
entitled “Risk Factors” in the quarterly and annual reports that we file with
the SEC. Any forward-looking statements that we make in this press release
speak only as of the date of this press release. Except as required by law, we
assume no obligation to update forward-looking statements contained in this
press release whether as a result of new information, future events or
otherwise, after the date of this press release.

Ocugen Contact: 
Ken Inchausti
Head, Investor Relations & Communications
ken.inchausti@ocugen.com

Please submit investor-related inquiries to: IR@ocugen.com

Release – Sierra Metals to Release Q1-2022 Consolidated Financial Results on Wednesday May 11th, 2022



Sierra Metals to Release Q1-2022 Consolidated Financial Results on Wednesday May 11th, 2022

Research, News, and Market Data on Sierra Metals

Shareholder Conference Call and
Webcast will be held on Thursday May 12
th, 2022

TORONTO–(BUSINESS WIRE)– 
Sierra Metals Inc. (TSX: SMT) (NYSE American: SMTS) (BVL: SMT) (“Sierra Metals” or the “Company”) will release Q1-2022 financial results on Wednesday May 11th, 2022 after Market Close. Senior Management will also host a webcast and conference call on Thursday May 12th, 2022 at 11:00am EST. Details of the Conference Call and Webcast are as follows:

Via Webcast:

A live audio webcast of the meeting will be available on the Company’s website:

https://event.on24.com/wcc/r/3724262/ABA56A91A50DA5A991E18125DC207388

The webcast along with presentation slides will be archived for 180 days on www.sierrametals.com.

Via phone:

For those who prefer to listen by phone, dial-in instructions are below. To ensure your participation, please call approximately five minutes prior to the scheduled start time of the call.

US/CAN dial-in number (Toll Free): 1 844 200 6205
United States (Local): 1 646 904 5544
Canada dial-in number (Local): 1 226 828 7575
All other locations (International): +1 929 526 1599

Access code: 
020167

Press *1 to ask a question, *2 to withdraw your question, or *0 for operator assistance

About Sierra Metals

Sierra Metals Inc. is a diversified Canadian mining company with Green Metal exposure including increasing copper production and base metal production with precious metals byproduct credits, focused on the production and development of its Yauricocha Mine in Peru, and Bolivar and Cusi Mines in Mexico. The Company is focused on increasing production volume and growing mineral resources. Sierra Metals has recently had several new key discoveries and still has many more exciting brownfield exploration opportunities at all three Mines in Peru and Mexico that are within close proximity to the existing mines. Additionally, the Company also has large land packages at all three mines with several prospective regional targets providing longer-term exploration upside and mineral resource growth potential.

The Company’s Common Shares trade on the Bolsa de Valores de Lima and on the Toronto Stock Exchange under the symbol “SMT” and on the NYSE American Exchange under the symbol “SMTS”.

For further information regarding Sierra Metals, please visit www.sierrametals.com or contact:

Continue to Follow, Like and
Watch our progress:

Webwww.sierrametals.com | Twittersierrametals | FacebookSierraMetalsInc | LinkedInSierra Metals Inc | Instagramsierrametals

Investor Relations
Sierra Metals Inc.
Tel: +1 (416) 366-7777
Email: 
info@sierrametals.com

Luis Marchese
CEO

Sierra Metals Inc.
Tel: +1 (416) 366-7777

Source: Sierra Metals Inc.